<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erlotinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erlotinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Erlotinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11364" href="/d/html/11364.html" rel="external">see "Erlotinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166466"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tarceva</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866773"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Erlotinib;</li>
<li>NAT-Erlotinib;</li>
<li>PMS-Erlotinib;</li>
<li>Tarceva;</li>
<li>TEVA-Erlotinib</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166486"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F166469"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d337555c-c886-452f-b980-d00486e5f2bf">Non–small cell lung cancer, metastatic, in patients with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, in patients with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations (as first-line therapy, maintenance treatment, or for progressive disease):</b>
<b>Oral: </b>150 mg once daily until disease progression or unacceptable toxicity (Cappuzzo 2010; Rosell 2012; Shepherd 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label combinations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">First-line treatment, advanced disease:<b> Oral: </b>150 mg once daily (in combination with ramucirumab) until disease progression or unacceptable toxicity (Nakagawa 2019). <b></b></p>
<p style="text-indent:-2em;margin-left:6em;">Nonsquamous non–small cell lung cancer (advanced or recurrent disease): <b>Oral: </b>150 mg once daily (in combination with bevacizumab) until disease progression or unacceptable toxicity (Saito 2019).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a983aa4f-a0e1-48aa-aa1f-efea85a3db07">Pancreatic cancer, locally advanced, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, locally advanced, unresectable or metastatic:</b>
<b>Oral:</b> 100 mg once daily (in combination with gemcitabine); continue until disease progression or unacceptable toxicity (Moore 2007).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5cb8148-b090-4cf3-b767-34e6d864972e">Renal cell carcinoma, papillary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, papillary (advanced) (off-label use): Oral:</b> 150 mg once daily (in combination with bevacizumab) until disease progression or unacceptable toxicity (Srinivasan 2014) <b>or</b> 150 mg once daily (as monotherapy) until disease progression or unacceptable toxicity (Gordon 2009).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant smoking:</b> Avoid tobacco smoking if possible. If unavoidable, increase erlotinib dose at 2-week intervals in 50 mg increments to a maximum dose of 300 mg (with careful monitoring); immediately reduce erlotinib dose to recommended starting dose (based on indication) upon smoking cessation.</p></div>
<div class="block dora drugH1Div" id="F50990851"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal impairment at treatment initiation:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied), although ~8% of a single dose is excreted in the urine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal toxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Grades 3/4 renal toxicity: Withhold erlotinib and consider discontinuing. If erlotinib is resumed, reinitiate with a 50 mg dose reduction after toxicity has resolved to baseline or ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">Renal failure associated with hepatorenal syndrome or due to dehydration: Withhold erlotinib until renal toxicity is resolved. If erlotinib is resumed, reinitiate with a 50 mg dose reduction after toxicity has resolved.</p></div>
<div class="block doha drugH1Div" id="F50988120"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment at treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Total bilirubin &gt; ULN or Child-Pugh classes A, B, and C: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution and monitor closely during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Total bilirubin &gt;3 times ULN: Use extreme caution.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been studied: A reduced starting dose (75 mg once daily) has been recommended in patients with hepatic dysfunction (AST ≥3 times ULN or direct bilirubin 1 to 7 mg/dL), with individualized dosage escalation if tolerated (Miller 2007); another study determined that pharmacokinetic and safety profiles were similar between patients with normal hepatic function and moderate hepatic impairment (O’Bryant 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Patients with normal hepatic function at baseline: If total bilirubin &gt;3 times ULN or transaminases &gt;5 times ULN: Interrupt erlotinib and consider discontinuing. If erlotinib is resumed, reinitiate with a 50 mg dose reduction after bilirubin and transaminases return to baseline or ≤ grade 1. Discontinue if hepatotoxicity does not improve within 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with baseline hepatic impairment or biliary obstruction: If bilirubin doubles or transaminases triple over baseline: Interrupt erlotinib and consider discontinuing. If erlotinib is resumed, reinitiate with a 50 mg dose reduction after bilirubin and transaminases return to baseline or ≤ grade 1. Discontinue if hepatotoxicity does not improve within 3 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatotoxicity that does not significantly improve or resolve within 3 weeks: Discontinue erlotinib.</p></div>
<div class="block dot drugH1Div" id="F166487"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Dermatologic toxicity:</i>
<b>Note:</b> Management of skin rashes that are not serious should include alcohol-free lotions, topical antibiotics, or topical corticosteroids, or if necessary, oral antibiotics and systemic corticosteroids; avoid exposure to sunlight (Kiyohara 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Bullous, blistering, or exfoliative skin toxicity (severe): Discontinue erlotinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe rash (unresponsive to medical management): Withhold erlotinib; may reinitiate with a 50 mg dose reduction after toxicity has resolved to baseline or ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>GI toxicity:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Diarrhea: Manage with loperamide; in persistent, severe diarrhea (unresponsive to loperamide) or dehydration due to diarrhea, withhold erlotinib; may reinitiate with a 50 mg dose reduction after toxicity has resolved to baseline or ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">GI perforation: Discontinue erlotinib.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Ocular toxicities:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Acute or worsening ocular toxicities (eg, eye pain): Interrupt erlotinib and consider discontinuing. If erlotinib is resumed, reinitiate with a 50 mg dose reduction after toxicity has resolved to baseline or ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:4em;">Corneal perforation or severe ulceration: Discontinue erlotinib.</p>
<p style="text-indent:-2em;margin-left:4em;">Keratitis (grade 3 or 4 or grade 2 persisting &gt;2 weeks): Withhold erlotinib; may reinitiate with a 50 mg dose reduction after toxicity has resolved to baseline or ≤ grade 1.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pulmonary symptoms:</i> Acute onset (or worsening) of pulmonary symptoms (eg, dyspnea, cough, fever): Withhold erlotinib while evaluating for drug-induced interstitial lung disease; if resuming erlotinib, reinitiate with a 50 mg dose reduction after symptoms resolve to ≤ grade 1 or baseline. Discontinue erlotinib permanently with development/confirmation of interstitial lung disease.</p></div>
<div class="block doe drugH1Div" id="F166470"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F166436"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with monotherapy in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Paronychia (14%), pruritus (13% to 16%), skin rash (60% to 85%; including acne vulgaris, bullous dermatitis [≤1%], dermal ulcer, desquamation, eczema, exfoliative dermatitis [≤1%], folliculitis, furuncle, hyperpigmentation, palmar-plantar erythrodysesthesia, skin fissure), xeroderma (12% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (52%), decreased appetite (≥30%), diarrhea (20% to 62%; grades 3/4: ≤6%), mucosal swelling (18%), nausea (33%; grade 3: 3%), stomatitis (17%; grade 3: &lt;1%), vomiting (≥20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (≥30%), fatigue (52%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (13%), back pain (19%), musculoskeletal pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (12% to 18%), eye disease (≤18%; including abnormal eyelash growth, decreased lacrimation, dry eye syndrome [12%], keratitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (48%), dyspnea (41% to 45%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Hepatic: Abnormal hepatic function tests (including increased serum alanine aminotransferase [grades ≥2: 3% to 4%], increased serum aspartate aminotransferase, increased serum bilirubin [grades ≥2: 5%])</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal perforation</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Severe renal disease</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy (Nagashio 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Costa 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute peptic ulcer with hemorrhage (gastritis, peptic ulcer) (Kim 2010), gastrointestinal hemorrhage, hematemesis, hematochezia, melena</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (acute) (Saif 2008), hepatorenal syndrome (Gunturu 2010), hepatotoxicity (Kunimasa 2012, Yamanaka 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Corneal ulcer (Tamura 2020), ophthalmic inflammation, uveitis (including anterior uveitis [Ali 2011])</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Cho 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease (Tsubata 2012), pneumonitis (Vahid 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Radiation recall phenomenon (Graziani 2014)</p></div>
<div class="block coi drugH1Div" id="F166450"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer’s US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Hypersensitivity to erlotinib or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F166434"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Cerebrovascular accidents, MI, and myocardial ischemia have been reported (some fatal).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Bullous, blistering, and/or exfoliating skin conditions, some suggestive of Stevens-Johnson or toxic epidermal necrolysis (TEN), have been reported (some fatal). An acne-like rash commonly appears on the face, back, and upper chest. Generalized or severe acneiform, erythematous or maculopapular rash may occur. Skin rash may correlate with treatment response (Kiyohara 2013; Wacker 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI perforation: GI perforation (including fatalities) has been reported; risk for perforation is increased with concurrent anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based-chemotherapy, and patients with history of peptic ulcers or diverticular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Microangiopathic hemolytic anemia (MAHA) with thrombocytopenia has been reported (rarely) with erlotinib in combination with gemcitabine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Elevated INR and bleeding events (including fatal hemorrhage) have been reported when erlotinib was administered concomitantly with warfarin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatic failure and hepatorenal syndrome have been reported (some fatal), particularly in patients with baseline hepatic impairment (although have also been observed in patients with normal hepatic function).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Corneal perforation and ulceration have been reported; decreased tear production, abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis have also been reported and are known risk factors for corneal ulceration/perforation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Rare, sometimes fatal, interstitial lung disease (ILD) has occurred; symptoms include acute respiratory distress syndrome, interstitial pneumonia, obliterative bronchiolitis, pneumonitis (including radiation and hypersensitivity), pulmonary fibrosis, and pulmonary infiltrates. The onset of symptoms has been within 5 days to more than 9 months after treatment initiation (median: 39 days).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Acute renal failure (some fatal), renal insufficiency, and hepatorenal syndrome have been reported, either secondary to hepatic impairment at baseline or due to severe dehydration; use with caution in patients with or at risk for renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• NSCLC: Some factors which correlate positively with response to EGFR-tyrosine kinase inhibitor (TKI) therapy in NSCLC include patients who have never smoked, EGFR mutation, and patients of Asian origin. EGFR mutations, specifically exon 19 deletions and exon 21 mutation (L858R), are associated with better response to erlotinib in patients with NSCLC (Riely 2006). Erlotinib treatment is not recommended in patients with NSCLC with <i>K-ras</i> mutations; they are not likely to benefit from erlotinib treatment (Eberhard 2005; Miller 2008). <i>K-ras</i> mutations correlated with poorer outcome with EGFR-TKI therapy in patients with NSCLC (Jackman 2009; Masarelli 2007; Shepherd 2005). The cobas EGFR mutation test has been approved to detect EGFR mutation for NSCLC treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Smokers: Erlotinib levels may be lower in patients who smoke; advise patients to stop smoking. Smokers treated with 300 mg/day exhibited steady-state erlotinib levels comparable to former- and never-smokers receiving 150 mg/day (Hughes 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for metastatic NSCLC treatment based on EGFR exon 19 deletions and exon 21 mutation (L858R) in tumor or plasma specimens; if these mutations are not detected in plasma specimen, tumor tissue (if available) may be tested.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose intolerance: Product may contain lactose; avoid use in patients with congenital lactase deficiency, glucose-galactose malabsorption, or glucose intolerance.</p></div>
<div class="block foc drugH1Div" id="F166444"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tarceva: 25 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tarceva: 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 100 mg, 150 mg</p></div>
<div class="block geq drugH1Div" id="F166432"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F166452"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Erlotinib HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $54.07 - $103.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $268.87 - $283.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $298.97 - $321.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tarceva Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $108.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $298.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $338.06</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866774"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tarceva: 25 mg, 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 100 mg, 150 mg</p></div>
<div class="block adm drugH1Div" id="F166447"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> The manufacturer recommends administration on an empty stomach (at least 1 hour before or 2 hours after the ingestion of food).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Acid-reducing agents: Avoid concomitant use with proton pump inhibitors (if possible). If taken with an H<sub>2</sub>-receptor antagonist, administer erlotinib 10 hours after the H<sub>2</sub>-receptor antagonist dose and ≥2 hours prior to the next H<sub>2</sub>- receptor dose. If an antacid is necessary, separate dosing by several hours.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">If necessary, an oral suspension may be prepared if patients are unable to swallow tablets whole (see Extemporaneously Prepared).</p></div>
<div class="block hazard drugH1Div" id="F49132487"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F166446"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic:</b> Treatment of metastatic non–small cell lung cancer (NSCLC) in tumors with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an approved test either as first-line, maintenance, or as second or greater line treatment after progression following at least 1 prior chemotherapy regimen.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Use in combination with platinum-based chemotherapy is not recommended. Safety and efficacy of treatment for metastatic NSCLC with EGFR mutations other than exon 19 deletion or exon 21 (L858R) substitution have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Based on the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) guidelines for therapy for stage IV NSCLC with driver mutations, erlotinib (either as monotherapy or in combination with either ramucirumab or bevacizumab) may be offered to patients with stage IV NSCLC and EGFR driver alterations if osimertinib is not available (ASCO/CCO [Hanna 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, locally advanced, unresectable or metastatic:</b> First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer (in combination with gemcitabine).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Guideline recommendations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">According to ASCO guidelines for locally advanced, unresectable pancreatic cancer, if disease progression occurs following induction with an initial systemic combination therapy regimen, treatment according to guidelines for metastatic pancreatic cancer should be offered (in appropriate patients) (ASCO [Balaban 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">The updated ASCO guidelines for metastatic pancreatic cancer recommend gemcitabine monotherapy as first-line therapy (when there is a preference for cancer-directed treatment) in patients with an ECOG performance status of 2 or a comorbidity profile that prohibits more aggressive therapy; erlotinib may be added to gemcitabine (with proactive dose/schedule adjustments to minimize toxicities) in this setting (ASCO [Sohal 2020]).</p></div>
<div class="block off-label drugH1Div" id="F55863287"><span class="drugH1">Use: Off-Label: Adult</span><p>Renal cell carcinoma, papillary (advanced)</p></div>
<div class="block mst drugH1Div" id="F2138083"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Erlotinib may be confused with afatinib, crizotinib, dacomitinib, enasidenib, encorafenib, entrectinib, erdafitinib, eribulin, gefitinib, imatinib, lapatinib, lorlatinib, neratinib, nintedanib, osimertinib, regorafenib, SUNItinib, vandetanib.</p>
<p style="text-indent:-2em;margin-left:4em;">Tarceva may be confused with Tresiba.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F166479"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F166438"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Erlotinib. Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of Erlotinib. Management: Avoid the concomitant use of erlotinib and moderate CYP1A2 inducers if possible. If concomitant use is unavoidable, increase the erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Erlotinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Erlotinib. Management: Avoid the combination of erlotinib and strong CYP3A4 inducers whenever possible. If this combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Erlotinib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of erlotinib-associated adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluvoxaMINE: May increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Erlotinib may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib.  Management: Avoid use of erlotinib with phenytoin when possible. If required, increase erlotinib dose by 50 mg increments at 2 week intervals, as tolerated, to a max of 450 mg/day. Also monitor for increased phenytoin concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Erlotinib. Management: Avoid use of this combination when possible. When the combination must be used, monitor the patient closely for the development of erlotinib-associated adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Histamine H2 Receptor Antagonists: May decrease the serum concentration of Erlotinib. Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the serum concentration of Erlotinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Erlotinib. Management: Avoid concomitant use of erlotinib with rifabutin when possible. If such a combination cannot be avoided, consider increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Erlotinib. Management: Avoid concomitant use of erlotinib with rifapentine when possible. If such a combination cannot be avoided, consider increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Erlotinib. Management: Avoid the combination of erlotinib and St John's wort whenever possible. If this combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of Erlotinib. Management: Avoid cigarette smoking during treatment with erlotinib whenever possible. If combined, increase erlotinib dose by 50 mg increments at 2-week intervals to a maximum of 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Erlotinib may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F166463"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Erlotinib bioavailability is increased with food. Grapefruit or grapefruit juice may decrease metabolism and increase erlotinib plasma concentrations. Management: Administer on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Avoid grapefruit and grapefruit juice. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake.</p></div>
<div class="block rep_considerations drugH1Div" id="F49168433"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential should use effective contraception during treatment and for at least 1 month after the last erlotinib dose.</p></div>
<div class="block pri drugH1Div" id="F166453"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Erlotinib crosses the placenta (Ji 2015; Jovelet 2015). Information related to the use of erlotinib in pregnancy is limited (Ji 2015; Rivas 2012; Zambelli 2008). Based on the mechanism of action and data from animal reproduction studies, erlotinib may cause fetal harm if administered in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F14383338"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if erlotinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant (including bullous and exfoliative skin disorders, diarrhea, hepatotoxicity, interstitial lung disease, microangiopathic hemolytic anemia with thrombocytopenia, and ocular disorders) lactating women should not breastfeed during treatment and for 2 weeks after the final erlotinib dose.</p></div>
<div class="block dic drugH1Div" id="F5028520"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit and grapefruit juice.</p></div>
<div class="block mop drugH1Div" id="F166442"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">LFTs (transaminases, bilirubin, and alkaline phosphatase [periodic], monitor more frequently in patients with hepatic impairment, biliary obstruction, or worsening liver function); renal function tests (periodic) and serum electrolytes (in patients at risk for dehydration; periodic); prothrombin time and INR (in patients on concomitant warfarin therapy); EGFR mutation status in patients with NSCLC adenocarcinoma (Keedy 2011); the cobas EGFR mutation test has been approved to detect EGFR mutation for first-line NSCLC treatment. Assess smoking status.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider a baseline ophthalmologic exam and reassess for ocular toxicities at 4 to 8 weeks after treatment initiation (Renouf 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor hydration status (for dehydration); monitor for signs/symptoms of pulmonary toxicity, dermatologic toxicity, and ocular toxicity. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F166433"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Erlotinib reversibly inhibits overall epidermal growth factor receptor (HER1/EGFR) - tyrosine kinase activity. Intracellular phosphorylation is inhibited which prevents further downstream signaling, resulting in cell death. Erlotinib has higher binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations than for the wild type receptor.</p></div>
<div class="block phk drugH1Div" id="F166449"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: ~60% on an empty stomach; food increases to ~100%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 232 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 93% to albumin and alpha<sub>1</sub>-acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP3A4 (major), CYP1A1 (minor), CYP1A2 (minor), and CYP1C (minor)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~100% when given with food; ~60% without food</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 36.2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily as metabolites: Feces (83%; 1% as unchanged drug); urine (8%; &lt;1% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51154049"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Smoking reduces erlotinib AUC by 64% (compared to former/never smokers); smokers had a 24% higher rate of erlotinib clearance.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869379"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bioborz | Elyp | Erloter</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib apotex | Erlotinib Cipla | Erlotinib sandoz | Tarceva</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Erlonix | Ertinib</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib sandoz | Tarceva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib actavis | Erlotinib heaton | Erlotinib sandoz | Erlotinib zentiva | Tarceva | Varlota</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de erlotinibe | Tarceva</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib sandoz | Tarceva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Erlocip | Tarceva</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib teva | Erlotinib vipharm | Erlotinib zentiva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Eraltin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib actavis | Erlotinib mylan | Tarceva | Varlota</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Lungitinib | Tarceva</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib Cipla | Erlotinib sandoz | Erlotinib tarbis | Erlotinib teva | Erlotinib tillomed</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Erlotaz</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib avansor | Erlotinib krka | Erlotinib orion | Erlotinib stada | Tarceva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib biogaran | Erlotinib eg | Erlotinib krka | Erlotinib mylan | Erlotinib sandoz | Erlotinib teva | Erlotinib zentiva | Tarceva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib | Erlotinib accord | Erlotinib glenmark | Erlotinib sandoz | Erlotinib zentiva | Tarceva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib/faran | Tarceva</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alvoceva | Erlotinib sandoz | Tarceva</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib actavis | Erlotinib PharmaS | Tarceva | Varlota</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib actavis | Erlotinib krka | Erlotinib mylan | Erlotinib sandoz | Erlotinib stada | Erlotinib vipharm | Varlota</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Erleva | Erlocip | Erlokem | Erlomy | Erlonat | Erlosam | Erlot | Erlotad | Erlotaz | Erlotec | Erlotero | Erlotib | Erlotirel | Lortinib | Tyrokinin | Zyceva</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib mylan | Erlotinib sandoz | Erlotinib tillomed | Tarceva</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Erlocip | Erlotaz | Tarceva | Tarlonib</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deceva | Eloceta | Erlotib | Ertinib | Tarceone | Tarceva | Teva erlotinib</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Erlocip e | Tarceva</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib mylan | Tarceva | Varlota</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib actavis | Erlotinib mylan | Erlotinib sandoz | Erlotinib zentiva | Tarceva | Varlota</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Binertil | Bisiprox | Ernat | Pritazel | Tarceva | Zulenit</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib accordpharma | Erlotinib CF | Erlotinib mylan | Erlotinib pharmamedic | Erlotinib sandoz | Erlotinib teva | Tarceva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib | Tarceva</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Biprolex | Rolit | Tarceva</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Erlonib | Erlotec | Tarceva</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib krka | Erlotinib vipharm</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib | Tarceva</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib mylan | Erlotinib sandoz | Erlotinib teva | Tarceva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Erluntas | Tarceva</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib glenmark | Erlotinib heaton | Erlotinib mylan | Erlotinib sandoz | Erlotinib zentiva | Varlota</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib | Erlotinib Nativ | Tarceva | Tarlenib</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib spc | Erloz | Pms erlotinib | Pulectus | Tarceva</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib avansor | Erlotinib glenmark | Erlotinib krka | Erlotinib medical valley | Erlotinib orion | Erlotinib sandoz | Erlotinib stada | Erlotinib teva | Tarceva</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib krka | Erlotinib teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Erlotinib mylan | Erlotinib sandoz | Erlotinib stada | Erlotinib teva | Erlotinib vipharm | Erlotinib zentiva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alvoceva | Erlonib | Erlotinib sandoz | Inerlotinib | Tarceva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ertinob | Etinib | Tarceva | Tarsinib</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Tarceva | Zyceva</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Tarceva</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Erlova</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Binit | Ercyta | Erlocip | Erlotinib adco | Erlotinib Cipla | Erlotinib zydus | Exoneo | Tarceva | Tarpib | Terlot</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22694887">
<a name="22694887"></a>Ali K, Kumar I, Usman-Saeed M, Usman Saeed M. Erlotinib-related bilateral anterior uveitis. <i>BMJ Case Rep</i>. 2011;2011:bcr0320113988. doi:10.1136/bcr.03.2011.3988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22694887/pubmed" id="22694887" target="_blank">22694887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(22):2654-2668. doi:10.1200/JCO.2016.67.5561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20493771">
<a name="20493771"></a>Cappuzzo F, Ciuleanu T, Stelmakh L, et al, “Erlotinib as Maintenance Treatment in Advanced Non-Small-cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase 3 Study,” <i>Lancet Oncol</i>, 2010, 11(6):521-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/20493771/pubmed" id="20493771" target="_blank">20493771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21388312">
<a name="21388312"></a>Cataldo VD, Gibbons DL, Pérez-Soler R, et al, “Treatment of Non-Small-Cell Lung Cancer With Erlotinib or Gefitinib,” <i>N Engl J Med</i>, 2011, 364(10):947-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21388312/pubmed" id="21388312" target="_blank">21388312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32364270">
<a name="32364270"></a>Cho SL, Lin WC, Chuang CA, Liao WY, Lai CF. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer. <i>Nephrology (Carlton)</i>. 2020;25(9):730. doi:10.1111/nep.13721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/32364270/pubmed" id="32364270" target="_blank">32364270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22277837">
<a name="22277837"></a>Ciuleanu T, Stelmakh L, Cicenas S, et al, “Efficacy and Safety of Erlotinib Versus Chemotherapy in Second-Line Treatment of Patients With Advanced, Non-Small-Cell Lung Cancer With Poor Prognosis (TITAN): A Randomised Multicentre, Open-Label, Phase 3 Study,” <i>Lancet Oncol</i>, 2012, 13(3):300-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22277837/pubmed" id="22277837" target="_blank">22277837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18090591">
<a name="18090591"></a>Costa DB, Kobayashi S, Schumer ST. Erlotinib-associated alopecia in a lung cancer patient. <i>J Thorac Oncol</i>. 2007;2(12):1136-1138. doi:10.1097/JTO.0b013e31815ba7f9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/18090591/pubmed" id="18090591" target="_blank">18090591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21610154">
<a name="21610154"></a>Coudert B, Ciuleanu T, Park K, et al, “Survival Benefit With Erlotinib Maintenance Therapy in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) According to Response to First-Line Chemotherapy,” <i>Ann Oncol</i>, 2012, 23(2):388-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21610154/pubmed" id="21610154" target="_blank">21610154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16043828">
<a name="16043828"></a>Eberhard DA, Johnson BE, Amler LC, et al, “Mutations in the Epidermal Growth Factor Receptor and in KRAS are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib,” <i>J Clin Oncol</i>, 2005, 23(25):5900-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/16043828/pubmed" id="16043828" target="_blank">16043828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884559">
<a name="19884559"></a>Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. <i>J Clin Oncol.</i> 2009;27(34):5788-5793. doi:10.1200/JCO.2008.18.8821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/19884559/pubmed" id="19884559" target="_blank">19884559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25503169">
<a name="25503169"></a>Graziani C, Hegde S, Saif MW. Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer. <i>Anticancer Res</i>. 2014;34(12):7339-7343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/25503169/pubmed" id="25503169" target="_blank">25503169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818124">
<a name="20818124"></a>Gunturu KS, Abu-Khalaf M, Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. <i>JOP</i>. 2010;11(5):484-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/20818124/pubmed" id="20818124" target="_blank">20818124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33591844">
<a name="33591844"></a>Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. <i>J Clin Oncol</i>. 2021;39(9):1040-1091. doi:10.1200/JCO.20.03570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/33591844/pubmed" id="33591844" target="_blank">33591844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164205">
<a name="19164205"></a>Hughes AN, O’Brien ME, Petty WJ, et al, “Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers,” <i>J Clin Oncol</i>, 2009, 27(8):1220-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/19164205/pubmed" id="19164205" target="_blank">19164205</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19671843">
<a name="19671843"></a>Jackman DM, Miller VA, Cioffredi LA, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <i>Clin Cancer Res</i>. 2009;15(16):5267-5273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/19671843/pubmed" id="19671843" target="_blank">19671843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26181671">
<a name="26181671"></a>Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C. Successful treatment of non-small cell lung cancer with erlotinib throughout pregnancy. <i>JAMA Oncol</i>. 2015;1(6):838-840.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/26181671/pubmed" id="26181671" target="_blank">26181671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25851627">
<a name="25851627"></a>Jovelet C, Seck A, Mir O, et al. Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. <i>Ann Oncol</i>. 2015;26(7):1500-1504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/25851627/pubmed" id="25851627" target="_blank">25851627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21482992">
<a name="21482992"></a>Keedy VL, Temin S, Somerfield MR, et al, “American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy,” <i>J Clin Oncol</i>, 2011, 29(15):2121-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21482992/pubmed" id="21482992" target="_blank">21482992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581582">
<a name="20581582"></a>Kim YH, Masago K, Mishima M. Erlotinib and gastrointestinal ulcer. <i>J Thorac Oncol</i>. 2010;5(7):1108-1109. doi:10.1097/JTO.0b013e3181e07f29<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/20581582/pubmed" id="20581582" target="_blank">20581582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23602600">
<a name="23602600"></a>Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. <i>J Am Acad Dermatol.</i> 2013:69(3);463-472. doi:10.1016/j.jaad.2013.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/23602600/pubmed" id="23602600" target="_blank">23602600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22333382">
<a name="22333382"></a>Kunimasa K, Yoshioka H, Iwasaku M, et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. <i>Intern Med</i>. 2012;51(4):431-434. doi:10.2169/internalmedicine.51.6285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22333382/pubmed" id="22333382" target="_blank">22333382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192. doi: 10.1592/phco.31.2.164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18487575">
<a name="18487575"></a>Lee SM, Buchler T, Joseph T, et al, “Bilateral Eardrum Perforation After Long-Term Treatment With Erlotinib,” <i>J Clin Oncol</i>, 2008, 26(15):2582-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/18487575/pubmed" id="18487575" target="_blank">18487575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23078958">
<a name="23078958"></a>Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2012;13(11):1161-1170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/23078958/pubmed" id="23078958" target="_blank">23078958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27543577">
<a name="27543577"></a>Li Q, Liu Z, Kolli S, et al. Stability of extemporaneous erlotinib, lapatinib, and imatinib oral suspension.<i> Am J Health Syst Pharm.</i> 2016;73(17):1331-1337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/27543577/pubmed" id="27543577" target="_blank">27543577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17634483">
<a name="17634483"></a>Miller AA, Murry DJ, Owzar K, et al, “Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101,” <i>J Clin Oncol</i>, 2007, 25(21):3055-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/17634483/pubmed" id="17634483" target="_blank">17634483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18349398">
<a name="18349398"></a>Miller VA, Riely GJ, Zakowski MF, et al, “Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib,” <i>J Clin Oncol</i>, 2008, 26(9):1472-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/18349398/pubmed" id="18349398" target="_blank">18349398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17452677">
<a name="17452677"></a>Moore MJ, Goldstein D, Hamm J, et al, “Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group,” <i>J Clin Oncol</i>, 2007, 25(15):1960-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/17452677/pubmed" id="17452677" target="_blank">17452677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34497169">
<a name="34497169"></a>Nagashio K, Tajiri K, Sato K, Ieda M. Erlotinib-induced cardiomyopathy in a patient with metastatic non-small cell lung cancer. <i>Int Heart J</i>. 2021;62(5):1171-1175. doi:10.1536/ihj.21-130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/34497169/pubmed" id="34497169" target="_blank">34497169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31591063">
<a name="31591063"></a>Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2019;20(12):1655-1669. doi:10.1016/S1470-2045(19)30634-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/31591063/pubmed" id="31591063" target="_blank">31591063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21938545">
<a name="21938545"></a>O'Bryant CL, Haluska P, Rosen L, et al, “An Open-Label Study to Describe Pharmacokinetic Parameters of Erlotinib in Patients With Advanced Solid Tumors With Adequate and Moderately Impaired Hepatic Function,” <i>Cancer Chemother Pharmacol</i>, 2012, 69(3):605-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21938545/pubmed" id="21938545" target="_blank">21938545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22649132">
<a name="22649132"></a>Renouf DJ, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. <i>J Clin Oncol</i>. 2012;30(26):3277-3286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22649132/pubmed" id="22649132" target="_blank">22649132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16467097">
<a name="16467097"></a>Riely GJ, Pao W, Pham D, et al, “Clinical Course of Patients With Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated With Gefitinib or Erlotinib,” <i>Clin Cancer Res</i>, 2006, 12(3 Pt 1):839-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/16467097/pubmed" id="16467097" target="_blank">16467097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22534670">
<a name="22534670"></a>Rivas G, Llinás N, Bonilla C, Rubiano J, Cuello J, Arango N. Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma. <i>Lung Cancer</i>. 2012;77(2):469-472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22534670/pubmed" id="22534670" target="_blank">22534670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22285168">
<a name="22285168"></a>Rosell R, Carcereny E, Gervais R, et al, “Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial,” <i>Lancet Oncol</i>, 2012, 13(3):239-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22285168/pubmed" id="22285168" target="_blank">22285168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18391918">
<a name="18391918"></a>Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. <i>Clin Adv Hematol Oncol</i>. 2008;6(3):191-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/18391918/pubmed" id="18391918" target="_blank">18391918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30975627">
<a name="30975627"></a>Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. <i>Lancet Oncol</i>. 2019;20(5):625-635. doi:10.1016/S1470-2045(19)30035-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/30975627/pubmed" id="30975627" target="_blank">30975627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16014882">
<a name="16014882"></a>Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al, “Erlotinib in Previously Treated Non-Small-Cell Lung Cancer,” <i>N Engl J Med</i>, 2005, 353(2):123-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/16014882/pubmed" id="16014882" target="_blank">16014882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17538162">
<a name="17538162"></a>Siu LL, Soulieres D, Chen EX, et al, “Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study,” <i>J Clin Oncol</i>, 2007, 25(16):2178-83. doi: 10.1200/JCO.2006.07.6547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/17538162/pubmed" id="17538162" target="_blank">17538162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14701768">
<a name="14701768"></a>Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. <i>J Clin Oncol</i>. 2004;22(1):77-85. doi:10.1200/JCO.2004.06.075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/14701768/pubmed" id="14701768" target="_blank">14701768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Srinivasan.1">
<a name="Srinivasan.1"></a>Srinivasan R, Su D, Stamatakis L, et al. Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib. <i>Eur J Cancer</i>. 2014;50(suppl 6):8. https://www.ejcancer.com/article/S0959-8049(14)70131-5/pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32483873">
<a name="32483873"></a>Tamura M, Takai Y, Nakamura S, Ohira A. A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis. <i>Acta Ophthalmol</i>. 2020;98(8):e1055-e1056. doi:10.1111/aos.14454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/32483873/pubmed" id="32483873" target="_blank">32483873</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genetech USA Inc; October 2016.</div>
</li>
<li>
<div class="reference">
                  Tarceva (erlotinib) [product monograph]. Mississauga, Ontario, Canada: Hoffman- La Roche Canada; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531540">
<a name="22531540"></a>Tsubata Y, Hamada A, Sutani A, Isobe T. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. <i>J Cancer Res Ther</i>. 2012;8(1):154-156. doi:10.4103/0973-1482.95201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/22531540/pubmed" id="22531540" target="_blank">22531540</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 4, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17464382">
<a name="17464382"></a>Vahid B, Esmaili A. Erlotinib-associated acute pneumonitis: report of two cases. <i>Can Respir J</i>. 2007;14(3):167-170. doi:10.1155/2007/832605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/17464382/pubmed" id="17464382" target="_blank">17464382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606725">
<a name="17606725"></a>Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. <i>Clin Cancer Res</i>. 2007;13(13):3913-3921. doi:10.1158/1078-0432.CCR-06-2610<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/17606725/pubmed" id="17606725" target="_blank">17606725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943548">
<a name="28943548"></a>Yamanaka Y, Sekine A, Kato T, et al. Afatinib therapy for brain metastases aggravated by a reduction in the dose of erlotinib due to the development of hepatotoxicity. <i>Intern Med</i>. 2017;56(21):2895-2898. doi:10.2169/internalmedicine.8638-16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/28943548/pubmed" id="28943548" target="_blank">28943548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18063195">
<a name="18063195"></a>Zambelli A, Prada GA, Fregoni V, Ponchio L, Sagrada P, Pavesi L. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy. <i>Lung Cancer</i>. 2008;60(3):455-457.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/18063195/pubmed" id="18063195" target="_blank">18063195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21783417">
<a name="21783417"></a>Zhou C, Wu YL, Chen G, et al, “Erlotinib Versus Chemotherapy as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802): A Multicentre, Open-Label, Randomised, Phase 3 Study,” <i>Lancet Oncol</i>, 2011,12(8):735-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erlotinib-drug-information/abstract-text/21783417/pubmed" id="21783417" target="_blank">21783417</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8736 Version 319.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
